- Home
- IPHA
as 07-26-2024 4:00pm EST
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 230.4M | IPO Year: | 2019 |
| Target Price: | $11.50 | AVG Volume (30 days): | 6.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $3.15 | Next Earning Date: | 09-12-2024 |
| Revenue: | $68,490,000 | Revenue Growth: | 6.88% |
| Revenue Growth (this year): | -42.15% | Revenue Growth (next year): | 105.84% |
Latest Innate Pharma S.A. ADS News
IPHA Breaking Stock News: Dive into IPHA Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
Business Wire
a month ago
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
MT Newswires
a month ago
Innate Pharma Reports 'Promising and Durable' Results From Phase 1/2 Monotherapy Targeting Blood Cancers
Business Wire
a month ago
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Business Wire
2 months ago
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
Business Wire
2 months ago
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Business Wire
2 months ago
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
Business Wire
2 months ago
Outcome of Innate Pharma’s 2024 Annual General Meeting
Compare IPHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPHA Innate Pharma S.A. ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.